MAL-ED Metabolic: A Follow-Up of Chronic Disease at Puberty
Launched by UNIVERSITY OF VIRGINIA · Nov 3, 2021
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The MAL-ED Metabolic trial aims to explore how early life factors, like growth and intestinal infections, can affect health as children reach puberty. Researchers are particularly interested in understanding how these early challenges might lead to issues like insulin resistance (which can cause diabetes) and other metabolic problems later in life. The study will follow children who were part of a previous research project called the MAL-ED study, where they were monitored for growth and infections in their early years. Now, as these children approach puberty, the researchers will look at their current health to see if there's a connection between their early life experiences and any signs of chronic diseases.
To participate in this study, kids must have been part of the original MAL-ED cohort. The trial is not yet recruiting participants, but once it begins, eligible children aged between 3 and 6 years will be assessed for their health and growth patterns. Participants can expect to undergo various health checks, which will help researchers learn more about how early life conditions impact long-term health. Overall, this study seeks to identify ways to improve health outcomes for children by understanding the links between their early experiences and future health risks.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participated in original MAL-ED cohort
- Exclusion Criteria:
- • Did not participate in original MAL-ED cohort
About University Of Virginia
The University of Virginia (UVA) is a prestigious academic institution renowned for its commitment to advancing medical research and improving patient care through innovative clinical trials. With a focus on interdisciplinary collaboration, UVA leverages its extensive resources and expertise in various fields, including medicine, engineering, and public health, to drive cutting-edge studies that address pressing health challenges. The university's clinical trial programs aim to translate scientific discoveries into effective treatments, ensuring the highest standards of ethical practice and participant safety. Through its strong emphasis on community engagement and education, UVA fosters a culture of research that not only contributes to the scientific community but also enhances the well-being of the populations it serves.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Mark D DeBoer, MD
Principal Investigator
University of Virginia
Estomih Mduma, MPH
Study Director
Haydom Global Health Research Centre
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials